URMC Labs - Department of Pathology & Laboratory Medicine

Neuroendocrine Prostate References

  • Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM, Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists, Anticancer Res 1994; 14:1215-20.
  • Abrahamsson PA, Cockett AT, di Sant'Agnese PA, Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma, Prostate Suppl 1998; 8:37-42.
  • Abrahamsson PA, Falkmer S, Falt K, Grimelius L, The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker", Pathol Res Pract 1989; 185:373-80.
  • Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L, Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate, Pathol Res Pract 1987; 182:298-307.
  • Ahel MZ, Kovacic K, Tarle M. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis. Anticancer Res. 2001; 21(2B):1363-6.
  • Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA, Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment, Prostate 2000; 42:274-9.
  • Albrecht M, Doroszewicz J, Gillen S, Gomes I, Wilhelm B, Stief T, Aumuller G. Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1beta with IL-1beta acting as a modulator of cellular differentiation. Prostate. 2004; 58:82-94.
  • Allard P, Beaulieu P, Aprikian A, Chevalier S,Bombesin modulates the association of Src with a nuclear 110-kd protein expressed in dividing prostate cells, J Androl 2000; 21:367-75.
  • Allen FJ, Van Velden DJ, Heyns CF, Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br J Urol 1995; 75:751-4.
  • Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod OK, Waldum HL, Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate, Prostate 1997B; 31:110-7.
  • Aprikian AG, Cordon-Cardo C, Fair WR, Zhang ZF, Bazinet M, Hamdy SM, et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma, J Urol 1994; 151:914-9.
  • Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J, Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells, J Mol Endocrinol 1996; 16:297-306.
  • Aprikian AG, Tremblay L, Han K, Chevalier S, Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins, Int J Cancer 1997; 72: 498-504.
  • Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al, Circulating neuroendocrine markers in patients with prostate carcinoma, Cancer 2000; 88:2590-7.
  • Berruti A, Dogliotti L, Mosca A, Tarabuzzi R, Torta M, Mari M, Gorzegno G, et al, Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients, Prostate 2001; 47:205-11.
  • Bohrer MH, Schmoll J. Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas, Verh Dtsch Ges Pathol 1993; 77:107-10.
  • Bollito E, Berruti A, Bellina M, Mosca A, Leonardo E, Tarabuzzi R, Cappia S, Ari MM, Tampellini M, Fontana D, Gubetta L, Angeli A, Dogliotti L. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol. 2001;12 (Suppl 2):S159-64.
  • Bonkhoff H, Wernert N, Dhom G, Remberger K, Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate, Prostate 1991; 19:91–98.
  • Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells, Hum Pathol 1995; 26:167–170.
  • Bonkhoff H and Remberger K, Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model, Prostate 1996; 28:98-106.
  • Bonkhoff H, Fixemer T, Hunsicker I, Remberger K, Simultaneous detection of DNA fragmentation (apoptosis), cell proliferation (MIB-1), and phenotype markers in routinely processed tissue sections, Virchows Arch 1999; 434:71-3.
  • Borre M, Nerstrom B, Overgaard J, Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting, Clin Cancer Res 2000; 6:1882-90.
  • Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L, Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival, J Urology 2002; 168:1204-1211.
  • Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, et al, Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy, J Pathol 1996; 78:437-41.
  • Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, et al, Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo, J Urol 1999; 162:1800-5.
  • Busby JE, Shih SJ, Yang JC, Kung HJ, Evans CP, Angiogenesis is not mediated by prostate cancer neuropeptides, Angiogenesis 2003; 6:289-93.
  • Casella R, Bubendorf L, Sauter G, Moch H, Mihatsch MJ, Gasser TC, Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies, J Urol 1998; 160:406-10.
  • Chevalier S, Defoy I, Lacoste J, Hamel L, Guy L, Begin LR, Aprikian AG. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Mol Cell Endocrinol. 2002;189:169-79.
  • Chuang CK, Wu TL, Tsao KC, Liao SK. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. J Formos Med Assoc. 2003; 102:480-5.
  • Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM, Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines, Prostate 2000; 42:1-7.
  • Cohen MK, Arber DA, Coffield KS, Keegan GT, McClintock J, Speights VO Jr, Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression, Cancer 1994; 74:1899-903.
  • Cohen RJ, Glezerson G, Haffejee Z, Neuro-endocrine cells-a new prognostic parameter in prostate cancer, Br J Urol 1991; 68:258-62.
  • Collado B, Gutierrez-Canas I, Rodriguez-Henche N, Prieto JC, Carmena MJ, Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells, Regul Pept 2004; 119:69-75.
  • Cox ME, Deeble PD, Lakhani S, Parsons SJ, Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression, Cancer Res 1999; 59:3821-30.
  • Cox ME, Deeble PD, Bissonette EA, Parsons SJ, Activated 3', 5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line, J Biol Chem 2000; 275:13812-8.
  • Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, et al, Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma, J Urol 1996; 155:340-3.
  • de Pinieux G, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Goncalves R, Dutrillaux AM, Nemati F, Oudard S, Lidereau R, Broqua P, Junien JL, Dutrillaux B, Poupon MF. Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol. 2001;159:753-64.
  • Deftos LJ, Nakada S, Burton DW, di Sant'Agnese PA, Cockett AT, Abrahamsson PA, Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate, Urology 1996; 48:58-62.
  • Dema A, Raica M, Tudose N, Prognostic significance of neuroendocrine differentiation in carcinoma of the prostate, Rom J Morphol Embryol 1996; 42:83-8.
  • di Sant'Agnese PA, de Mesy Jensen KL, Churukian CJ, Agarwal MM, Human prostatic endocrine-paracrine (APUD) cells, Distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains, Arch Pathol Lab Med 1985; 109:607-12.
  • Diaz M, Abdul M, Hoosein N, Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and –2, Prostate Suppl 1998; 8:32-6.
  • Dizeyi N, Konrad L, Bjartell A, Wu H, Galdaleanu V, Hansson J, Helboe L, Abrahamsson P-A, Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines, Urologic Oncology 2002; 7:91-98.
  • Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA, Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines, Prostate 2004; 59:328-36.
  • Evans AL, Humphrey PA, Srigley, Large cell neuroendocrine carcinoma of the prostate, Mod Pathol 2004; 17 (supplement 1):150A (abst).
  • Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ, Expression of early growth response genes in human prostate cancer, Cancer Res 1998; 58:2461-8.
  • Elek J, Pinzon W, Park KH, Narayanan R, Relevant genomics of neurotensin receptor in cancer, Anticancer Res 2000; 20:53-8.
  • Erasmus CE, Verhagen WI, Wauters CA, van Lindert EJ. Brain metastasis from prostate small cell carcinoma: not to be neglected. Can J Neurol Sci. 2002; 29:375-7.
  • Ferrero-Pous M, Hersant AM, Pecking A, Bresard-Leroy M, Pichon MF. Serum chromogranin-A in advanced prostate cancer. BJU Int. 2001;88:790-6.
  • Festuccia C, Guerra F, D'Ascenzo S, Giunciuglio D, Albini A, Bologna M, In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin, Int J Cancer 1998; 75:418-31.
  • Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate. 2002;53:118-23.
  • Foster BA, Evangelou A, Gingrich JR, Kaplan PJ, DeMayo F, Greenberg NM. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation. 2002;70:624-32.
  • Furuya Y, Ohta S, Ito H, Apoptosis of androgen-independent mammary and prostate cell lines induced by topoisomerase inhibitors: common pathway of gene regulation, Anticancer Res 1997; 17:2089-93.
  • Garabedian EM, Humphrey PA, Gordon JI, A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells (prostatic intraepithelial neoplasia), Proc Natl Acad Sci 1998; 95: 15382-15387.
  • Goodin JL, Rutherford CL, Identification of differentially expressed genes during cyclic adenosine monophosphate-induced neuroendocrine differentiation in the human prostatic adenocarcinoma cell line LNCaP, Molecular Carcinogenesis 2002; 33:88-98.
  • Grobholz R, Boher MH, Siegsmund M, Junemann K-P, Bley U, and Woenckhaus M, Correlation between neovascularization and neuroendocrine differentiation in prostatic carcinoma, Pathol Res Pract 2000; 196:277-84.
  • Ghannoum JE, DeLellis RA, Shin SJ, Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report, Int J Surg Pathol 2004; 12:167-70.
  • Halmos G, Schally A, Sun B, Davis R, Bostwick D, Plonowski A, High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers, J Clinical Endocrinology & Metabolism 2000; 85:2564-2571.
  • Hansson J, Bjartell A, Gadaleanu V, Dizeyi N, Abrahamsson P-A, Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer, The Prostate 2002; 53:50-59.
  • Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K, Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells, Br J Cancer 1996; 74:910-6.
  • Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer. 2002; 95:1415-20.
  • Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N, Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy, Eur Urol 2004; 45:586-92.
  • Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z, Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype, Clin Cancer Res 2001; 7:2941-8.
  • Hoosein NM, Logothetis CJ, Chung LW, Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells, J Urol 1993; 149:1209-13.
  • Hu Y, Ippolito JE, Garabedian EM, Humphrey PA, Gordon JI. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem. 2002; 277:44462-74
  • Hu Y, Wang T, Stormo GD, Gordon JI, RNA interference of achaete-scute homolog 1 in mouse prostate neuroendocrine cells reveals its gene targets and DNA binding sites, Proc Natl Acad Sci U S A 2004; 101:5559-64.
  • Huang J. and di Sant'Agnese PA. Neuroendocrine differentiation in prostate cancer: an overview IN Advances in oncology: the expanding role of octreotide I. Ed. SWJ Lamberts and L Dogliotti. BioScientifica Ltd, Bristol, UK 2002 p. 243-262.
  • Huss WJ, Gregory CW, Smith GJ, Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence, Prostate 2004; 60:91-7.
  • Hussain A, Dawson N, Management of advanced/metastatic prostate cancer: update, Oncology (Huntingt) 2000; 14:1677-88.
  • Hvamstad T, Jordal A, Hekmat N, Paus E, Fossa SD. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol. 2003;44:215-21.
  • Ischia R, Hobisch A, Bauer R, Weiss U, Gasser RW, Horninger W, et al, Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate, J Urol 2000; 163:1161-4.
  • Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002;41:289-96.
  • Ismail AH, Altaweel W, Chevalier S, Kassouf W, Aprikian AG. Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer, Can J Urol. 2004;11:2146-50.
  • Ismail HR, Landry AF, Aprikian AG, Chevalier S, Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate, The Prostate 2002; 51: 117-125.
  • Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol. 2002;167:512-5.
  • Ito T, Yamamoto S, Ohno Y, Namiki K, Aizawa T, Akiyama A, Tachibana M. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol Rep. 2001; 8:1221-4.
  • Iwamura M, Hellman J, Cockett AT, Lilja H, Gershagen S, Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen, Urology 1996; 48:317-25.
  • Jiborn T, Bjartell A, Abrahamsson PA, Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment, Urology 1998; 51:585-9.
  • Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 2004;64:5489-95
  • Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, et al, Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model, Am J Pathol 1999; 154:543-51.
  • Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, et al, Androgen deprivation of the PC-310 human prostate cancer model system induces neuroendocrine differentiation, Cancer Res 2000; 60:741-8.
  • Jongsma J, Oomen MH, Noordzij MA, Romijn JC, van Der Kwast TH, Schroder FH, et al, Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines, Prostate 2000B; 42:34-44.
  • Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJM, van der Kwast TH, Schroeder FH, van Steenbrugge GJ, Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation, The Prostate 2002; 50:203-215.
  • Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol. 1991;146:358-61.
  • Kamiya N, Akakura K, Suzuki H, Isshiki S, Komiya A, Ueda T, Ito H. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol. 2003 Sep;44(3):309-14
  • Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM, Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model, Prostate 2003; 55:219-37.
  • Kawai S, Hiroshima K, Tsukamoto Y, Tobe T, Suzuki H, Ito H, Ohwada H, Ito H. Small cell carcinoma of the prostate expressing prostate-specific antigen and showing syndrome of inappropriate secretion of antidiuretic hormone: an autopsy case report. Pathol Int. 2003;53:892-6.
  • Kim J, Adam RM, Freeman MR. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res. 2002;62:1549-54.
  • Kollermann J, Helpap B. Neuroendocrine differentiation and short-term neoadjuvant hormonal treatment of prostatic carcinoma with special regard to tumor regression. Eur Urol. 2001;40:313-7.
  • Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH, The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy, J Urol 1997; 158:171-4.
  • Krupski T, Petroni GR, Frierson HF Jr, Theodorescu JU, Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate, Urology 2000; 55:743-9.
  • Kyprianou N, Isaacs JT, "Thymineless" death in androgen-independent prostatic cancer cells, Biochem Biophys Res Commun 1989; 165:73-81.
  • Lee L-F, Guan J, Qiu Y, Kung H-J, Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase, Molecular and Cellular Biology 2001; 21:8385-8397.
  • Levine L, Lucci JA 3rd, Pazdrak B, Cheng JZ, Guo YS, Townsend CM Jr, Hellmich MR. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res. 2003; 63:3495-502.
  • Li GZ, Zeng L, Zhang J, Yuan YM, Yang XY, Wang JH, Na YQ, Guo YL. Impact of short-term neoadjuvant hormonal treatment on neuroendocrine differentiation in prostate carcinoma. Zhonghua Zhong Liu Za Zhi. 2003; 25:493-5.
  • Lilleby W, Paus E, Skovlund E, Fossa SD, Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer, Prostate 2001; 46:126-33.
  • Magni P, Motta M. Expression of neuropeptide Y receptors in human prostate cancer cells. Ann Oncol. 2001;12 (Suppl 2):S27-9.
  • Mariot P, Vanoverberghe K, Lalevee N, Rossier MF, Prevarskaya N. Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem. 2002;277:10824-33.
  • Markwalder R, Reubi JC, Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation, Cancer Res 1999; 59:1152-9.
  • Martin R, Fraile B, Peinado F, Arenas MI, Elices M, Alonso L, et al, Immunohistochemical localization of protein gene product 9.5, ubiquitin, and neuropeptide Y immunoreactivities in epithelial and neuroendocrine cells from normal and hyperplastic human prostate, J Histochem Cytochem 2000; 48:1121-30.
  • Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM,Tsukamoto T, Shappell SB, Matusik RJ, A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic protential, Cancer Research 2001; 61:2239-2249.
  • Masumori N, Tsuchiya K, Tu WH, Lee C, Kasper S, Tsukamoto T, Shappell SB, Matusik RJ. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol. 2004; 171:439-42.
  • Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G, Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients, Prostate 2000; 45:72-9.
  • McWilliam LJ, Manson C, George NJ, Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma, Br J Urol 1997; 80:287-90.
  • Meyer-Siegler K. COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4-2b prostate cancer cells. Mol Med. 2001;7:850-60
  • Miyoshi Y, Uemura H, Kitami K, Satomi Y, Kubota Y, Hosaka M. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int. 2001;88:982-3.
  • Moody TW, Mayr CA, Gillespie TJ, Davis TP, Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines, Peptides 1998; 19:253-8.
  • Mori S, Murakami-Mori K, Bonavida B, Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells, Biochem Biophys Res Commun 1999; 257:609-14.
  • Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H, et al, Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines, Cancer Lett 2000; 155:173-9.
  • Nagakawa O, Furuya Y, Fujiuchi Y, Fuse H. Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma. Urology. 2002 ; 60:527-30.
  • Noordzij MA, van der Kwast TH, van Steenbrugge GJ, Hop WJ, Schroder FH, The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy, Int J Cancer 1995; 62:252-8.
  • Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002; 20:3072-80.
  • Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, et al, Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression, Nat Med 1998; 4:50-7.
  • Parker SL, Tong T, Bolden S, Wingo PA, Cancer statistics, 1997. CA Cancer J Clin 1997; 47:5-27.
  • Pearse AG, The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept, J Histochem Cytochem 1969; 17:303-13.
  • Petit T, Davidson KK, Lawrence RA, von Hoff DD, Izbicka E, Neuropeptide receptor status in human tumor cell lines, Anticancer Drugs 2001; 12:133-6.
  • Pretl K, Zur frage der endokrinie der menschilchen vorsteherdruse, Virchows Arch (A) 1944; 312:392-404.
  • Qiu Y, Robinson D, Pretlow TG, Kung HJ, Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells, Proc Natl Acad Sci U S A 1998; 95:3644-9.
  • Qiu Y, Ravi L, Kung HJ, Requirement of ErbB2 for signaling by interleukin-6 in prostate carcinoma cells, Nature 1998B; 393:83-5.
  • Regnauld K, Nguyen QD, Vakaet L, Bruyneel E, Launay JM, Endo T, Mareel M, Gespach C, Emami S. G-protein alpha(olf) subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells. Oncogene. 2002;21:4020-31.
  • Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res. 2002; 8:1139-46.
  • Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA, Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis, Prostate 1997; 30:183-7.
  • Rocchi P, Boudouresque F, Zamora AJ, Muracciole X, Lechevallier E, Martin PM, et al, Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines, Cancer Res 2001; 61:1196-206.
  • Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol. 2003; 34:646-53.
  • Roudier MP, True LD, Vessella RL, Higano CS. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity, J Clin Pathol. 2004; 57:321-3.
  • Rumpold H, Heinrich E, Untergasser G, Hermann M, Pfister G, Plas E, Berger P. Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 2002; 53:101-108.
  • Salazar EP, Rozengurt E, Bombesin and platelet-derived growth factor induce association of endogenous focal adhesion kinase with Src in intact Swiss 3T3 cells, J Biol Chem 1999; 274:28371-8.
  • Salido M, Vilches J, Lopez A, Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines, Histol Histopathol 2000; 15:729-38.
  • Salido M, Vilches J, Roomans GM, Changes in elemental concentrations in LNCaP cells are associated with a protective effect of neuropeptides on etoposide-induced apoptosis, Cell Biol Int 2004; 28:397-402.
  • Santamaria L, Martin R, Martin JJ, Alonso L. Stereologic estimation of the number of neuroendocrine cells in normal human prostate detected by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2002;10:275-81.
  • Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology. 2003; 62(5 Suppl 1):11-20.
  • Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate. 2003 ; 55:168-79.
  • Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE, Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations, Prostate 1997: 31:183-92.
  • Segal NH, Cohen RJ, Haffejee Z, Savage N, BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell, Arch Pathol Lab Med 1994; 118:616-8.
  • Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, Kakudo K, Katsuoka Y. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int. 2001; 51(6):452-9.
  • Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ, Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer, Proc Natl Acad Sci U S A 1994; 91:4673-7.
  • Sehgal I, Thompson TC, Neuropeptides induce Mr 92,000 type IV collagenase (matrix metalloprotease-9) activity in human prostate cancer cell lines, Cancer Res 1998; 58:4288-91.
  • Shimizu T, Ohta Y, Ozawa H, Matsushima H, Takeda K, Papaverine combined with prostaglandin E2 synergistically induces neuron-like morphological changes and decrease of malignancy in human prostatic cancer LNCaP cells, Anticancer Res 2000; 20:761-7.
  • Sim SJ, Glassman AB, Ro JY, Lee JJ, Logothetis CJ, Liu FJ, Serum calcitonin in small cell carcinoma of the prostate, Ann Clin Lab Sci 1996; 26:487-95.
  • Speights VO Jr, Cohen MK, Riggs MW, Coffield KS, Keegan G, Arber DA, Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples, Br J Urol 1997; 80:281-6.
  • Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med. 2002;27:11-7.
  • Spiotto MT, Chung TD, STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP, Prostate 2000; 42:88-98.
  • Spiotto MT, Chung TD, STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells, Prostate 2000; 42:186-95.
  • Steineck G, Reuter V, Kelly WK, Frank R, Schwartz L, Scher HI. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol. 2002; 41:668-74
  • Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z, Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway, Am J Pathol 2003; 162:655-63.
  • Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, et al, Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling, J Clin Invest 2000; 106:1399-407.
  • Sun B, Halmos G, Schally AV, Wang X, Martinez M, Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers, Prostate 2000; 42:295-303.
  • Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MA, Milbrandt J, EGR1 target genes in prostate carcinoma cells identified by microarray analysis, The Journal of Biological Chemistry 2000; 275:38524-38531.
  • Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O, Shimazaki J. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol. 2001;8:431-6
  • Tarle M, Ahel MZ, Kovacic K. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res. 2002;22:2525-9.
  • Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr, Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate, Cancer 1997; 80:2109-19.
  • Thigpen AE, Cala KM, Guileyardo JM, Molberg KH, McConnell JD, Russell DW, Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma, J Urol 1996;155:975-81.
  • True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA, Norwood T, Liu A, Ellis W, Lange P, Vessella R, Animal model: a neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49, Am J Path 2002; 161:705-715.
  • Tyagi A, Agarwal C, Agarwal R. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol Cancer Ther. 2002;1:525-32.
  • Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bonnal JL, Mauroy B, Shuba Y, Skryma R, Prevarskaya N. Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ. 2004; 11:321-30.
  • Vilches J, Salido M, Fernandez-Segura E, Roomans GM, Neuropeptides, apoptosis and ion changes in prostate cancer. Methods of study and recent developments, Histol Histopathol 2004; 9:951-61.
  • Wang Q, Horiatis D, Pinski J, Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation, Int J Cancer 2004; 111:508-13.
  • Wasilenko WJ, Palad AJ, Somers KD, Blackmore PF, Kohn EC, Rhim JS, et al, Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines, Int J Cancer 1996; 68:259-64.
  • Wasilenko WJ, Cooper J, Palad AJ, Somers KD, Blackmore PF, Rhim JS, et al, Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP, Prostate 1997; 30:167-73.
  • Weinstein MH, Partin AW, Veltri RW, Epstein JI, Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy, Hum Pathol 1996; 27:683-7.
  • Wernert N, Kern L, Heitz P, Bonkhoff H, Goebbels R, Seitz G, et al, Morphological and immunohistochemical investigations of the utriculus prostaticus from the fetal period up to adulthood, Prostate 1990; 17:19-30.
  • Wilson EM, Oh Y, Hwa V, Rosenfeld RG. Interaction of IGF-binding protein-related protein 1 with a novel protein, neuroendocrine differentiation factor, results in neuroendocrine differentiation of prostate cancer cells. J Clin Endocrinol Metab. 2001; 86:4504-11.
  • Wright ME, Tsai MJ, Aebersold R, Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells, Mol Endocrinol 2003; 17:1726-37.
  • Wu G, Burzon DT, di Sant'Agnese PA, Schoen S, Deftos LJ, Gershagen S, et al, Calcitonin receptor mRNA expression in the human prostate Urology 1996; 47:376-81.
  • Xiao D, Qu X, Weber HC. GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells. Regul Pept. 2002; 109:141-8.
  • Xiao D, Qu X, Weber HC. Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell Signal. 2003; 15:945-53.
  • Xie S, Lin HK, Ni J, Yang L, Wang L, di Sant'Agnese PA, Chang C, Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells, Prostate 2004; 60:61-7.
  • Xing N, Qian J, Bostwick D, Bergstralh E, Young CY, Neuroendocrine cells in human prostate over-express the anti-apoptosis protein surviving, Prostate 2001; 48:7-15
  • Xue Y, Verhofstad A, Lange W, Smedts F, Debruyne F, de la Rosette J, et al, Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: cell kinetic features of neuroendocrine cells in the human prostate, Am J Pathol 1997; 151:1759-65.
  • Xue Y, Smedts F, Verhofstad A, Debruyne F, de la Rosette J, Schalken J, Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: new perspectives, Prostate Suppl 1998; 8:62-73.
  • Xue Y, van der Laak J, Smedts F, Schoots C, Verhofstad A, de la Rosette J, et al, Neuroendocrine cells during human prostate development: does neuroendocrine cell density remain constant during fetal as well as postnatal life? Prostate 2000; 42:116-23.
  • Yashi M, Muraishi O, Kobayashi Y, Tokue A, Nanjo H, Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients, The Prostate 2002; 51:84-97.
  • Yashi M, Nukui A, Kurokawa S, Ochi M, Ishikawa S, Goto K, Kobayashi Y, Muraishi O, Tokue A. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate. 2003; 56:305-12.
  • Yu DS, Hsieh DS, Chen HI, Chang SY. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications. J Urol. 2001;166:871-5.
  • Zaky Ahel M, Kovacic K, Kraljic I, Tarle M. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Anticancer Res. 2001; 21(2B):1475-9.
  • Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin M, Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype, Biochim Biophys Acta 2001; 1539:28-43.
  • Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF, Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells, Oncogene 2003; 22:6704-16.
  • Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci U S A. 1999; 96:7490-5.

URMC Labs Test Index

A | B | C | D | E | F | G
H | I | J | K | L | M | N
O | P | Q | R | S | T | U
V | W | X | Y | Z